Cargando…
Subcutaneous bortezomib for multiple myeloma treatment: patients’ benefits
The use of novel agents such as thalidomide, lenalidomide, and bortezomib has considerably improved the outcome of multiple myeloma patients. Besides greater biological activity, these drugs unfortunately have also been associated with greater toxicity. To evaluate the positive effect on the quality...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Dove Medical Press
2014
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4094627/ https://www.ncbi.nlm.nih.gov/pubmed/25045252 http://dx.doi.org/10.2147/PPA.S38142 |